Zylox-Tonbridge Medical Technology Co., Ltd. has announced a discloseable transaction involving the acquisition of a 49% equity interest in Optimed Holding GmbH, a company organized under the laws of Germany. The transaction was made pursuant to a Sale and Purchase Agreement entered into on January 16, 2026, between Zylox-Tonbridge as the purchaser and E-Med Solutions as the seller. Completion of the proposed acquisition is subject to the fulfillment or waiver of certain conditions precedent as set forth in the agreement. Zylox-Tonbridge is principally engaged in the research, development, manufacturing, and sales of neuro- and peripheral vascular interventional products. The seller, E-Med Solutions, is primarily engaged in the development, manufacturing, and distribution of medical technology products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260116-11992684), on January 15, 2026, and is solely responsible for the information contained therein.